Lamotrigine (All indications)

Low birth weight (< 2500g)

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S8978
R30432
Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 Weight at birth <2500 g during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 1.15 [0.99;1.35] C 172/2,813   91,172/1,707,707 91,344 2,813
ref
S8974
R30418
Hernández-Díaz (Lamotrigine) (Mixed indications), 2014 Low birth weight (< 2500g) throughout pregnancy prospective cohort unexposed, disease free Adjustment: No 1.20 [0.71;2.03] C 74/1,581   18/457 92 1,581
ref
S8975
R30420
Kilic (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2014 Low birth weight (< 2500 g) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) excluded Adjustment: Yes 1.30 [1.00;1.80]
excluded (control group)
48/876   23,503/673,844 23,551 876
ref
S8976
R30423
Kilic (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2014 Low birth weight (< 2500 g) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: No Controls: epilepsy indication 1.17 [0.85;1.61] C 48/876   249/5,275 297 876
ref
S8902
R30063
Artama (Lamotrigine) (Controls unexposed, disease free), 2013 Low birth weight (< 2500g) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, disease free excluded Adjustment: Yes 0.99 [0.43;2.25]
excluded (control group)
6/173   21,546/719,509 21,552 173
ref
S8903
R30075
Artama (Lamotrigine) (Controls unexposed, sick), 2013 Low birth weight (< 2500g) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: Yes 0.96 [0.39;2.34] 6/173   65/1,793 71 173
ref
S8953
R30312
Veiby (Lamotrigine) (Controls unexposed, disease free) b, 2013 Low birth weight (< 2500 grams) during pregnancy (anytime or not specified) prospective cohort unexposed, disease free excluded Adjustment: Yes 1.20 [0.50;2.80]
excluded (control group)
6/103   5,024/106,899 5,030 103
ref
S8954
R30326
Veiby (Lamotrigine) (Controls unexposed, sick) b, 2013 Low birth weight (< 2500 grams) during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No 1.43 [0.55;3.75] C 6/103   16/386 22 103
ref
Total 5 studies 1.16 [1.02;1.32] 91,826 5,546
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020Coste, 2020 1 1.15[0.99; 1.35]91,3442,81373%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: moderateROB mesure: moderateROB reporting: moderate Hernández-Díaz (Lamotrigine) (Mixed indications), 2014Hernández-Díaz, 2014 2 1.20[0.71; 2.03]921,5816%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: moderate Kilic (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2014Kilic, 2014 3 1.17[0.85; 1.61]29787617%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Artama (Lamotrigine) (Controls unexposed, sick), 2013Artama, 2013 4 0.96[0.39; 2.34]711732%ROB confusion: moderateROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Veiby (Lamotrigine) (Controls unexposed, sick) b, 2013Veiby, 2013 5 1.43[0.55; 3.75]221032%ROB confusion: seriousROB selection: lowROB classification: lowROB missing: moderateROB mesure: moderateROB reporting: moderate Total (5 studies) I2 = 0% 1.16[1.02; 1.32]91,8265,5460.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Lamotrigine) (Controls unexposed NOS) (Mixed indications; 2: Lamotrigine) (Mixed indications; 3: Lamotrigine) (Controls unexposed, sick) (Mixed indications; 4: Lamotrigine) (Controls unexposed, sick; 5: Lamotrigine) (Controls unexposed, sick) ;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.16[1.02; 1.32]91,8265,5460%NACoste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 Hernández-Díaz (Lamotrigine) (Mixed indications), 2014 Kilic (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2014 Artama (Lamotrigine) (Controls unexposed, sick), 2013 Veiby (Lamotrigine) (Controls unexposed, sick) b, 2013 5 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.16[1.00; 1.34]91,4364,3940%NACoste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 Hernández-Díaz (Lamotrigine) (Mixed indications), 2014 2 unexposed, sickunexposed, sick 1.17[0.88; 1.55]3901,1520%NAKilic (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2014 Artama (Lamotrigine) (Controls unexposed, sick), 2013 Veiby (Lamotrigine) (Controls unexposed, sick) b, 2013 3 Tags Adjustment   - No  - No 1.16[1.02; 1.33]91,7555,3730%NACoste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 Hernández-Díaz (Lamotrigine) (Mixed indications), 2014 Kilic (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2014 Veiby (Lamotrigine) (Controls unexposed, sick) b, 2013 4   - Yes  - Yes 0.96[0.39; 2.35]71173 -NAArtama (Lamotrigine) (Controls unexposed, sick), 2013 1 Controls   - epilepsy indication  - epilepsy indication 1.17[0.85; 1.61]297876 -NAKilic (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2014 1 All studiesAll studies 1.16[1.02; 1.32]91,8265,5460%NACoste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 Hernández-Díaz (Lamotrigine) (Mixed indications), 2014 Kilic (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2014 Artama (Lamotrigine) (Controls unexposed, sick), 2013 Veiby (Lamotrigine) (Controls unexposed, sick) b, 2013 50.25.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-1.21.30.5910.000Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020Hernández-Díaz (Lamotrigine) (Mixed indications), 2014Kilic (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2014Artama (Lamotrigine) (Controls unexposed, sick), 2013Veiby (Lamotrigine) (Controls unexposed, sick) b, 2013

Asymetry test p-value = 0.8022 (by Egger's regression)

slope=0.1398 (0.0394); intercept=0.0718 (0.2624); t=0.2735; p=0.8022

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 8902, 8953, 8975

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.18[1.04; 1.34]141,5695,5460%NACoste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 Hernández-Díaz (Lamotrigine) (Mixed indications), 2014 Kilic (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2014 Artama (Lamotrigine) (Controls unexposed, disease free), 2013 Veiby (Lamotrigine) (Controls unexposed, disease free) b, 2013 5 unexposed, sick controlsunexposed, sick controls 1.17[0.88; 1.55]3901,1520%NAKilic (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2014 Artama (Lamotrigine) (Controls unexposed, sick), 2013 Veiby (Lamotrigine) (Controls unexposed, sick) b, 2013 30.510.01.0